SLAMF6 is an immune cell receptor whose function was not clear. Does it activate or inhibit cells? The results so far have been contradictory. Now, scientists at the Institut de Recherches Cliniques de Montréal (IRCM) have unveiled evidence that SLAMF6, a protein of the SLAM family that binds to copies of itself, is regulated by interactions between molecules of the same receptor within the same cell. Read More
Venture capital firms and research institutions have launched the European Life Science Coalition in a bid to strengthen Europe’s VC ecosystem by mobilizing more private and public investment. Read More
Changchun Genescience Pharmaceutical Co. Ltd. has received clearance from China’s National Medical Products Administration (NMPA) to start clinical trials with Gensci-136 for injection, a dual APRIL/BAFF antagonist in development for the treatment of immunoglobulin A nephropathy. Read More
A recent study published in Molecular Therapy by researchers from West China Hospital at Sichuan University and collaborators aimed to investigate the effect of CaMKII gene therapy on retinal ganglion cell (RGC) protection in mouse models of retinal ischemia/reperfusion (I/R) injury and congenital glaucoma. Read More
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter. Read More
Chikungunya virus is a positive-sense single-stranded RNA virus for which no antiviral therapy has been approved. Nucleotide analogues are among the most promising broad-spectrum antivirals, as they inhibit viral RNA-dependent RNA polymerase, an essential enzyme for RNA virus replication. Read More
CSPC Pharmaceutical Group Ltd. has obtained IND approval from the FDA for SYH-2082 injection, a GLP-1/GIP receptor dual-biased agonist polypeptide long-acting injection for weight management for individuals with obesity or overweight and at least one weight-related comorbidity. Read More
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release. Read More
Scientists from Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a signal transducer and activator of transcription 6 (STAT6)- or STAT3-targeting moiety. Read More
Beijing Tide Pharmaceutical Co. Ltd. has identified serine/threonine-protein kinase ATR inhibitors reported to be useful for the treatment of cancer. Read More
Researchers have explored the effects of human umbilical cord mesenchymal stem cells (hUC-MSCs) on cognitive recovery in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, a rare, neuronal antibody-mediated disorder characterized by neuropsychiatric symptoms and impaired cognitive function. hUC-MSCs have previously shown immunomodulatory and anti-inflammatory properties. Read More
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described antibody-drug conjugates (ADCs) comprising antibodies targeting cadherin-3 (CDH3; CDHP; P-cadherin) covalently linked to cytotoxic drug through a linker. They are reported to be useful for the treatment of cancer. Read More
Researchers from Fudan University reported the development of CZL-077, a p300/CBP bromodomain inhibitor. p300 and CREB-binding protein (CBP) are closely related histone acetyltransferases that play central roles in regulating gene expression. Dysregulation of these proteins has been implicated in tumorigenesis and the development of therapy resistance. Read More
